EXEL
Exelixis, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -6.7% ·
share flow +7.4% ·
net new positions -7.1%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 343.80K | $18.50M | n/a | −1 |
| Q2 2026 | 137 | -1 | 179.98M | $9.79B | +5 | −8 |
| Q1 2026 | 143 | -1 | 180.18M | $7.73B | +4 | −6 |
| Q4 2025 | 143 | +1 | 192.52M | $8.44B | +2 | n/a |
| Q3 2025 | 20 | -1 | 116.93M | $4.83B | n/a | −2 |
| Q2 2025 | 19 | +2 | 115.09M | $5.07B | +2 | n/a |
| Q1 2025 | 14 | -1 | 52.64M | $1.94B | +1 | −2 |
| Q4 2024 | 15 | +1 | 49.00M | $1.63B | +1 | n/a |
| Q3 2024 | 13 | 0 | 34.27M | $889.30M | n/a | n/a |
| Q2 2024 | 13 | n/a | 31.74M | $712.85M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Renaissance Technologies ✦ | 14.82M | -3.1% | $547.31M | 0.8% | ▼ Trim | 4 | SEC ↗ |
| 2 | State Street Global Advisors ✦ (passive) | 11.79M | +3.3% | $435.27M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 7.42M | +43.8% | $273.90M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 4 | AQR Capital Management ✦ | 6.89M | +73.8% | $250.87M | 0.3% | ▲ Add | 4 | SEC ↗ ×5 |
| 5 | Arrowstreet Capital ✦ | 3.68M | +16.5% | $135.94M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 6 | Norges Bank ✦ (passive) | 2.86M | +0.6% | $105.75M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | T. Rowe Price ✦ | 1.62M | -8.4% | $59.76M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 8 | Two Sigma Investments ✦ | 1.60M | +20.4% | $59.05M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 9 | D. E. Shaw & Co. ✦ | 712.58K | -56.1% | $26.31M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 10 | Gotham Asset Management ✦ | 559.32K | +30.7% | $20.65M | 0.2% | ▲ Add | 4 | SEC ↗ |
| 11 | Millennium Management ✦ | 475.05K | -64.5% | $17.54M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 12 | Wellington Management ✦ | 148.20K | +7.1% | $5.47M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 13 | Fisher Asset Management ✦ | 45.28K | +1.0% | $1.67M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | Bridgewater Associates ✦ | 8.31K | New | $306,990 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Bridgewater Associates | $306,990 | 0.0% |
Exited
| Marshall Wace | $11.26M | was 0.0% |
| Citadel Advisors | $5.32M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 692 holders, 256.72M shares, $10.43B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 9.81K sh · $526,512
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
5.6% of class · View original SEC filing ↗